149 related articles for article (PubMed ID: 36754615)
1. Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy.
Mirjačić Martinović K; Vuletić A; Tišma Miletić N; Matković S; Gavrilović D; Ninković A; Jurišić V; Babović N
J Clin Pathol; 2024 Apr; 77(5):343-351. PubMed ID: 36754615
[TBL] [Abstract][Full Text] [Related]
2. Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients.
Mirjačić Martinović K; Vuletić A; Tišma Miletić N; Besu Žižak I; Milovanović J; Matković S; Jurišić V
Transl Oncol; 2023 Dec; 38():101799. PubMed ID: 37806113
[TBL] [Abstract][Full Text] [Related]
3. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
[TBL] [Abstract][Full Text] [Related]
4. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
6. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.
Frauchiger AL; Mangana J; Rechsteiner M; Moch H; Seifert B; Braun RP; Dummer R; Goldinger SM
Br J Dermatol; 2016 Apr; 174(4):823-30. PubMed ID: 26659191
[TBL] [Abstract][Full Text] [Related]
8. Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A; Doyen J; Cremoni M; Bailly L; Zorzi K; Ruetsch-Chelli C; Brglez V; Picard-Gauci A; Troin L; Esnault VLM; Passeron T; Montaudié H; Seitz-Polski B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088741
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab.
Popović A; Petković I; Dimitrijevic A; Jović A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):86-91. PubMed ID: 38006368
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
Xu J; Zhao J; Wang J; Sun C; Zhu X
Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
[TBL] [Abstract][Full Text] [Related]
13. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
15. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
16. TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma.
Crucitta S; Cucchiara F; Marconcini R; Bulleri A; Manacorda S; Capuano A; Cioni D; Nuzzo A; de Jonge E; Mathjissen RHJ; Neri E; van Schaik RHN; Fogli S; Danesi R; Del Re M
Front Mol Biosci; 2024; 11():1288677. PubMed ID: 38633217
[No Abstract] [Full Text] [Related]
17. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment.
Su S; Chen F; Lv X; Qi L; Ding Z; Ren W; Wei M; Liu Y; Yu L; Liu B; Wang L
Cancer Immunol Immunother; 2024 Jan; 73(1):12. PubMed ID: 38231411
[TBL] [Abstract][Full Text] [Related]
19. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract][Full Text] [Related]
20. Serum TNF-α level and probing depth as a combined indicator for peri-implant disease.
Yilihamujiang H; Ni X; Yu M; Dong S; Mei L; Zheng Y; Cheng L; Pang N
Braz J Med Biol Res; 2024; 57():e12989. PubMed ID: 38265340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
